- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different" Episode 5: Policy and Biosimilars
“If legislators want to be able to tell their constituents that they acted on drug prices this year, this is the vehicle to do it. There is nothing else with this kind of support and with this kind of impact sitting before legislators right now,” said Christine Simmon, JD, executive director of the Biosimilars Council, about the bipartisan CREATES Act.
Our guest on this episode of “Not So Different” is Christine Simmon, JD, the executive director of the Association for Accessible Medicines’ (AAM) Biosimilars Council.
Simmon joined The Center for Biosimilars® via phone to discuss recent comments from FDA Commissioner, Scott Gottlieb, MD, on challenges in the US biosimilars market, and a potential legislative solution—the bipartisan CREATES Act—that could help to address some of those challenges.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
